ERBB2 and gastric cancer: Trastuzumab is a biotherapeutic monoclonal antibody that thwarts the signaling of human epidermal growth factor receptor 2 (HER2), and it is specifically employed in the treatment of breast and gastric cancers, characterized by high levels of HER2 expression [1].